匹多莫德联合左氧氟沙星预防女性反复泌尿系感染复发100例

孙晓东

（河北省廊坊市人民医院，河北 廊坊 065000）

匹多莫德联合左氧氟沙星预防女性反复泌尿系感染复发100例

孙晓东

（河北省廊坊市人民医院，河北 廊坊 065000）

目的 评估匹多莫德联合氟喹诺酮类药物预防女性泌尿系感染复发的有效性和安全性。方法 200例复发性泌尿系感染患者治愈后，随机均分为对照组和治疗组，各100例。对照组患者给予小剂量左氧氟沙星抑菌治疗，每次0．1 g，每日1次；治疗组患者在对照组治疗基础上加用匹多莫德片治疗，每次0．4 g，每日1次。两组患者均治疗6个月并随访6个月，比较泌尿系感染复发率。结果 治疗组患者在治疗期间、随访期前3个月、随访期后3个月感染复发率分别为5．00%，10．00%，11．00%，分别低于对照组的8．00%，19．00%，21．00%（P＜0．05）。治疗过程中，治疗组和对照组患者不良反应发生率分别为3．00%和2．00%，无显著性差异。结论 匹多莫德联合氟喹诺酮类药物可以有效预防女性泌尿系感染的复发，且无明显不良反应，值得临床推广。

匹多莫德；氟喹诺酮类；泌尿系感染；复发性；女性

复发性泌尿系感染的患者多见于体质较差的青年育龄妇女、老年女性、糖尿病等自身免疫力较差的患者，急性期抗菌治疗后临床多采取低剂量氟喹诺酮类药物抑菌治疗，但临床治疗效果欠佳。匹多莫德为免疫调节剂，可有效提高患者的免疫功能，目前也常用于泌尿系感染的辅助治疗，但对其用于复发性泌尿系感染患者的系统研究尚未见报道。为此，本研究观察了匹多莫德联合氟喹诺酮预防女性复发性泌尿系感染的有效性和安全性，为临床治疗提供参考。

Clinical Observation of Pidotimod plus Levofloxacin for Preventing Female Recurrent Urinary Tract Infection in 100 Cases

Sun Xiaodong
(Langfang Municipal People′s Hospital,Langfang,Hebei,China 065000)

Objective To evaluate the efficacy and safety of pidotimod plus fluoroquinolones in the prevention of female recurrent urinary tract infection．M ethods 200 patients with recurrent urinary tract infection after cure were randomly divided into two groups,100 cases in each group．The control group took low dose of levofloxacin 0．1 g,once daily;while on this basis the treatment group was added with Pidotimod Tablet 0．4 g，once daily．The two groups were treated for 6 months and followed up for 6 months．The relapsing rates of urinary system infection were compared between the two groups．Results The relapsing rates during the treatment period in the first 3 months of follow-up and the late 3 months of follow-up in the treatment group were 5．00%,10．00% and 11．00% respectively, which were lower than 8．00%,19．00% and 21．00% in the control group(P＜0．05)．The occurrence rates of adverse reactions during the treatment process in the treatment group and the control group were 3．00% and 2．00% respectively,but the differences had no statistical significance．Conclusion Pidotimod combined with fluoroquinolones can effectively prevent the recurrence of female urinary tract infection without obvious adverse reactions and deserves to be clinically promoted．

pidotimod;fluoroquinolones;urinary system infection;relapse;female

R969.4；R979.5

A

1006-4931(2015)05-0046-02